9 Biotechnology Stocks to Sell Now

Advertisement

For the current week, the overall ratings of nine biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, EPIRUS Biopharmaceuticals, Inc. (EPRS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). EPRS also rates an F in Portfolio Grader’s specific subcategory of Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

This is a rough week for Ohr Pharmaceutical Inc (OHRP). The company’s rating falls to D from the previous week’s C. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc.’s (TSRX) rating weakens this week, dropping to a D versus last week’s C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

Vical Incorporated (VICL) earns a D this week, falling from last week’s grade of C. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.

Tenax Therapeutics, Inc.’s (TENX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. Shares of the stock have been exchanging at an usually rapid pace, twice the rate of the week prior. The trailing PE Ratio for the stock is 107.30. For more information, get Portfolio Grader’s complete analysis of TENX stock.

Synergy Pharmaceuticals, Inc. (SGYP) experiences a ratings drop this week, going from last week’s D to an F. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of Feb. 24, 2015, 14.1% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.

The rating of Verastem, Inc. (VSTM) slips from a D to an F. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

Celldex Therapeutics, Inc. (CLDX) is having a tough week. The company’s rating falls from a C to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of Feb. 24, 2015, 25.1% of outstanding Celldex Therapeutics, Inc. shares were held short. Trade volume is up 957.2% from the previous week. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.

The rating of Trevena, Inc. (TRVN) declines this week from a C to a D. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/02/9-biotechnology-stocks-to-sell-now-eprs-ohrp-tsrx/.

©2024 InvestorPlace Media, LLC